Melasma Clinical Trial - Efficiency And Safety Of Association Arbutin,

Status Suspended

Clinical Trial Summary

The objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) in the treatment of epidermal melasma.

Clinical Trial Description

The melasma is a common hipermelanosis, acquired, symmetrical, with irregular occurring in areas such as photo-exposed face, forehead and temples, can affect the eyelids and tion. The facial regions most affected are: zigomatic (82.4%), parotid (64.7%), front (64.7%), mandible (35.3%) and nasal (35.3%). The injuries of melasma is variable increase of epidermal melanin and inflammatory infiltrate of mild to moderate intensity. Treatment with compounds such as hydroquinone and derivatives, tretinoin, corticosteroids moderate or combination of them all have shown good results, diminishing the training, reducing the stability and promoting the destruction of melanocytes. The primary objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) manufactured by Glenmark Laboratory, and as the comparator drug product Triluma ® (hydroquinone + fluocinolone + tretinoin), in the treatment of epidermal melasma through parameters of clinical course of the disease (improves) and its security. Patients who are included in the study will be randomly and automatically receive one of the treatments (New association or Triluma ®), which should use for 12 weeks. The products should be applied in the regions affected once a day, during night. The evaluation of clinical improvement, as well as security, will be held on periodic visits, as described below, which will be held the record and supply of medicines to patients. In each visit, beyond the clinical examination of photographs and large, it filled the Area and Severity Scale (Melasma Area and Severity Index - MASI), which quantifies the melasma and will be the main tool of control of clinical improvement. At the end of the study, data will be compared, showing no inferiority or inferiority of clinical drug testing in relation to the comparator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00717652
Study type	Interventional
Source	Azidus Brasil
Contact
Status	Suspended
Phase	Phase 2/Phase 3
Start date	July 2008
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05013801` - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma	N/A
Recruiting	`NCT06174545` - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma	N/A
Completed	`NCT01695356` - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma	Phase 4
Recruiting	`NCT06278948` - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma	N/A
Not yet recruiting	`NCT05911698` - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.	N/A
Recruiting	`NCT05656833` - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma	N/A
Recruiting	`NCT04597203` - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial	N/A
Completed	`NCT02138539` - Evaluation of an Herbal-Based De-Pigmenting System	Phase 4
Recruiting	`NCT01661556` - Clinical Trial of Hydroquinone Versus Miconazol in Melasma	Phase 4
Completed	`NCT01001624` - Melanil in the Treatment of Melasma	Phase 3
Terminated	`NCT03415685` - Lutronic PicoPlus Exploratory Clinical Trial	N/A
Recruiting	`NCT04765930` - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma	N/A
Completed	`NCT04137263` - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging	N/A
Recruiting	`NCT03686787` - Oral Tranexamic Acid and Laser for Treatment of Melasma	Phase 4
Completed	`NCT05969587` - Cysteamine Compared to Hydroquinone in Melasma	Phase 3
Completed	`NCT00500162` - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma	Phase 4
Completed	`NCT00472966` - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma	Phase 4
Completed	`NCT05887219` - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma	Phase 1
Completed	`NCT05884151` - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma	Phase 1
Recruiting	`NCT03308370` - Platelet Rich Plasma in Treatment of Melasma	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma — melasma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms